HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?

RMD Open. 2020 Feb;6(1):e001171. doi: 10.1136/rmdopen-2020-001171.

Authors

Elisa Gremese¹, Antonio Gasbarrini², Gianfranco Ferraccioli³

Affiliations

¹ Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy.
² Internal Medicine and Gastroenterology, Catholic University of the Sacred Heart, Rome, Lazio, Italy.
³ Division of Rheumatology, IRCCS, Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome, Italy gianfranco.ferraccioli@unicatt.it.

No abstract available

Keywords: DMARDs (biologic); DMARDs (synthetic); arthritis; infections; rheumatoid arthritis.

Publication types

Editorial

MeSH terms

Antirheumatic Agents / adverse effects
Antirheumatic Agents / pharmacology*
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid / drug therapy*
Biological Products / adverse effects
Biological Products / pharmacology*
Biological Products / therapeutic use
DNA, Viral / drug effects
DNA, Viral / genetics
Glucocorticoids / therapeutic use
Hepatitis B / drug therapy*
Hepatitis B / virology
Hepatitis B Surface Antigens / genetics
Hepatitis B virus / drug effects*
Hepatitis B virus / genetics
Hepatitis B virus / immunology
Humans
Immunosuppressive Agents / adverse effects
Janus Kinase Inhibitors / therapeutic use
Latent Infection / chemically induced
Latent Infection / prevention & control
Synthetic Drugs / adverse effects

Substances

Antirheumatic Agents
Biological Products
DNA, Viral
Glucocorticoids
Hepatitis B Surface Antigens
Immunosuppressive Agents
Janus Kinase Inhibitors
Synthetic Drugs